title: Identification of chromosomal loci associated with non-P-glycoprotein-mediated multidrug resistance to topoisomerase II inhibitor in lung adenocarcinoma cell line by comparative genomic hybridization.
abstract: In order to identify genomic changes associated with an etoposide resistance acquisition, we used comparative genomic hybridization (CGH) to compare a human lung adenocarcinoma cell line, A549 wild type, and three sublines, A549-VP1-3, exposed to increasing concentrations of the topoisomerase II inhibitor, VP16. R-banding karyotype, fluorescence in situ hybridization (FISH), and Southern blot for the MLL gene were also performed. The CGH analysis showed that the A549-VP3 cell line shared chemoresistance-specific abnormalities (amplification of 11q23-qter, loss of chromosome 17, and deletions of 2p14-pter and 2q23-q24). FISH analysis confirmed the loss of one chromosome 17 in the three resistant sublines and revealed an increased fragmentation of chromosome 2 in more than two segments, depending on the etoposide concentration. FISH with an MLL gene probe showed additional signals of MLL (from three in the A549-WT to seven in the A549-VP3 cell line) translocated onto several other chromosomes. Southern blot indicated an amplification of the MLL gene, dependent on the etoposide concentration, without gene rearrangement. The CGH results are suggestive of loci that could be associated with the acquisition of an etoposide-chemoresistant phenotype. Deletion of the 2p region has already been reported, without any candidate gene being identified. The role of MLL in leukemogenesis has previously been demonstrated, but its role in the development of other tumors or its significance in the chemoresistance process remains to be elucidated.
authors.affiliation: Laboratory of Hematology, Robert Debré Hospital and Medical Faculty (UPRES EA 20-70-IFR 53 Biomolecules), Reims, France.
authors.forename: S
authors.initials: S
authors.lastname: Struski
authors.forename: M
authors.initials: M
authors.lastname: Doco-Fenzy
authors.forename: A
authors.initials: A
authors.lastname: Trussardi
authors.forename: L
authors.initials: L
authors.lastname: Masson
authors.forename: N
authors.initials: N
authors.lastname: Gruson
authors.forename: E
authors.initials: E
authors.lastname: Ulrich
authors.forename: M
authors.initials: M
authors.lastname: Proult
authors.forename: J C
authors.initials: JC
authors.lastname: Jardillier
authors.forename: G
authors.initials: G
authors.lastname: Potron
authors.forename: P
authors.initials: P
authors.lastname: Cornillet-Lefebvre
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology; D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D015139:Blotting, Southern; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005047:Etoposide / Q000494:pharmacology*; D005819:Genetic Markers; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D009693:Nucleic Acid Hybridization; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004791:Enzyme Inhibitors; D005819:Genetic Markers; D059005:Topoisomerase II Inhibitors; D005047:Etoposide